Wang Tuo, Cao Cong, Fan Yu, Xu Jialing, Hua Tao, Ding Jie, Liu Zejie, Wang Beili, Lian Juanwen
Department of Oncology, Xi'an Chest Hospital, Xi'an, 710100, Shaanxi, China.
Discov Oncol. 2024 Mar 11;15(1):72. doi: 10.1007/s12672-024-00914-4.
GABPB1, the gene that encodes two isoforms of the beta subunit of GABP, has been identified as an oncogene in multiple malignant tumors. However, the role and mode of action of GABPB1 in malignant tumors, especially in lung cancer, are not well understood and need further research.
Our research focused on examining the biological function of GABPB1 in NSCLC (Non-Small Cell Lung Cancer). We analysed tumor data from public databases to assess the expression of GABPB1 in NSCLC and its correlation with patient prognosis and investigated GABPB1 expression and methylation patterns in relation to the tumor microenvironment. In parallel, experiments were conducted using short hairpin RNA (shRNA) to suppress the GABPB1 gene in human lung cancer cells to evaluate the effects on cell proliferation, viability, and apoptosis.
GABPB1 was widely expressed in various tissues of the human body. Compared to that in normal tissues, the expression of this gene was different in multiple tumor tissues. GABPB1 was highly expressed in lung cancer tissues and cell lines. Its expression was associated with molecular subtype and cellular signalling pathways, and a high level of GABPB1 expression was related to a poor prognosis in lung adenocarcinoma patients. The expression and methylation of GABPB1 affect the tumor microenvironment. After suppressing the expression of GABPB1 in both A549 and H1299 cells, we found a decrease in cell growth and expression, the formation of clones and an increase in the apoptosis rate.
Our research verified that GABPB1 promotes the tumorigenesis of NSCLC and has an inhibitory effect on tumor immunity. The specific role of GABPB1 may vary among different pathological types of NSCLC. This molecule can serve as a prognostic indicator for lung adenocarcinoma, and its methylation may represent a potential breakthrough in treatment by altering the tumor immune microenvironment in lung squamous cell carcinoma. The role and mechanism of action of GABPB1 in NSCLC should be further explored.
GABPB1基因编码GA结合蛋白β亚基的两种异构体，已被确定为多种恶性肿瘤中的致癌基因。然而，GABPB1在恶性肿瘤尤其是肺癌中的作用和作用模式尚未完全明确，需要进一步研究。
我们的研究聚焦于检测GABPB1在非小细胞肺癌（NSCLC）中的生物学功能。我们分析了来自公共数据库的肿瘤数据，以评估GABPB1在NSCLC中的表达及其与患者预后的相关性，并研究了GABPB1表达和甲基化模式与肿瘤微环境的关系。同时，使用短发夹RNA（shRNA）在人肺癌细胞中抑制GABPB1基因，以评估对细胞增殖、活力和凋亡的影响。
GABPB1在人体各种组织中广泛表达。与正常组织相比，该基因在多种肿瘤组织中的表达有所不同。GABPB1在肺癌组织和细胞系中高表达。其表达与分子亚型和细胞信号通路相关，GABPB1高表达与肺腺癌患者预后不良有关。GABPB1的表达和甲基化影响肿瘤微环境。在A549和H1299细胞中抑制GABPB1的表达后，我们发现细胞生长和表达减少、克隆形成减少以及凋亡率增加。
我们的研究证实GABPB1促进NSCLC的肿瘤发生，并对肿瘤免疫有抑制作用。GABPB1的具体作用在不同病理类型的NSCLC中可能有所不同。该分子可作为肺腺癌的预后指标，其甲基化可能通过改变肺鳞癌的肿瘤免疫微环境代表治疗的潜在突破。GABPB1在NSCLC中的作用和作用机制应进一步探索。
